Current Law Journal Content
Washington & Lee Law School
  Current Law Journal Content
                  an index to legal periodicals
 


  Bio-Science Law Review   (United Kingdom)
  Volume 3, Issue 6, 1999/2000
  homepage                   other issues
 
  • ETHICS AS REGULATORY OBLIGATION IN THE FIELD OF NOVEL FOODS AND FOOD INGREDIENTS: A NOVEL OBLIGATION UNDER COMMUNITY LAW
        Brian Sheridan
        p.223                                                                                      +cite        
        The general safety and information requirements and detailed labelling obligations laid down in European Union Regulation 258/97 include a requirement to label products where 'ethical concerns' exist. At Community level, the time when ethical issues were primarily political in nature appears to be over. Using Regulation 258/97 as an example, this article discusses the substantive regulatory role of ethics in Community law and raises some issues of principle for future regulation of ethics at national and Community level.
  • PLANT VARIETY PROTECTION IN ASIA: SOME ISSUES OF IMPLEMENTATION AND IMPLICATIONS FOR GERMPLASM EXCHANGE NETWORKS
        Henrik Egelyng and Michael Blakeney
        p.227                                                                                      +cite        
        This article examines emerging plant variety protection ('PVP') regimes in an Asian context. Questions are raised as to how implementation of PVP legislation will affect existing networks for the exchange of rice varieties and improved rice germplasm. The emerging PVP regimes are investigated from a perspective of regulation and possible benefits from a regional division of labour in implementing plant variety protection.
  • EMEA AND THE MARKETING OF PHARMACEUTICALS ACROSS THE EUROPEAN UNION: ONE COUNTRY TWO SYSTEMS
        Claudio A Mereu and Philippe Delsaut
        p.234                                                                                      +cite        
        The authors offer an overview of the two systems of centralised and national authorisation procedures for marketing medicinal products. They focus particularly on the European centralised procedure and suggest future trends for this sector.